MedTrace Logo

BMS-741672 for Diabetic Neuropathic Pain

NCT00683423 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.

Conditions

  • Neuropathic Pain

Interventions

DRUG

BMS-741672

Tablets, Oral, 100 mg, once daily, 3 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683423 on ClinicalTrials.gov